Status:
ACTIVE_NOT_RECRUITING
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC. 27 patie...
Eligibility Criteria
Inclusion
- Patient with histologically confirmed advanced NSCLC (inoperable stage 3 or 4)
- Patient aged ≥ 18 years
- Life expectancy \> 3 months
- Patient naïve to treatment for NSCLC
- Patient hospitalized at least one night for initiation of specific treatment (chemotherapy, radiotherapy, surgery, other...)
- Patient with no other active cancer. Cancer history accepted if more than 3 years old and considered cured.
- Patient affiliated to a Social Security scheme in France.
- Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.
Exclusion
- Small-cell cancer or cancer with a majority small-cell contingent
- Patient previously treated for NSCLC
- Outpatient
- Patient with active pathology such as sepsis or uncontrolled inflammatory syndrome
- Any pathology contraindicating the sample collection procedures required by the study.
- Pregnant or breast-feeding women.
- Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical follow-up and/or procedures stipulated in the study protocol.
- Patients deprived of their liberty or under legal protection (guardianship, legal protection).
Key Trial Info
Start Date :
January 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT05988970
Start Date
January 29 2024
End Date
September 1 2025
Last Update
June 3 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Larrey
Toulouse, France
2
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France